Finoriq research workspace
Altimmune, Inc. (ALT) News
Read recent company news headlines and source links for Altimmune, Inc. (ALT).
Company Snapshot
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
- Company
- Altimmune, Inc. (ALT)
- Ticker
- ALT
- Market Cap
- $548.4M
- Latest Price
- $2.82
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.